GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Phase 1

Withdrawn

Conditions: Influenza

Interventions: Biological: Investigational H7N9 vaccine GSK3277510A
Biological: Investigational H7N9 vaccine GSK3277509A
Biological: Placebo

First Posted Date: 2014-06-30

Last Posted Date: 2016-06-20

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02177734

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Leukaemia, Myelocytic, Acute

Interventions: Drug: GSK2879552
Drug: ATRA

First Posted Date: 2014-06-30

Last Posted Date: 2019-06-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 41

Registration Number: NCT02177812

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

A Clinical Trial to Study the Impact of a Nutritional Beverage on Tests of Memory in Healthy Preschool Age Children

Not Applicable

Completed

Conditions: Cognition

Interventions: Other: Test beverage powder (High Proteins and added micronutrients)
Other: Control beverage powder (Low protein and no added micronutrients)

First Posted Date: 2014-06-30

Last Posted Date: 2019-04-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 528

Registration Number: NCT02177942

Locations: 🇮🇳
GSK Investigational Site, Karamsad, Gujarat, India

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Phase 3

Completed

Conditions: Infections, Meningococcal
Meningococcal Disease

Interventions: Biological: Bexsero®
Biological: Routine vaccines

First Posted Date: 2014-06-25

Last Posted Date: 2020-08-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 225

Registration Number: NCT02173704

Locations: 🇨🇳
GSK Investigational Site, Taipei, Taiwan

A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel

Phase 1

Completed

Conditions: Pain

Interventions: Drug: 0.2% Sodium Lauryl Sulfate
Drug: 0.9% Saline
Drug: 1% Diclofenac Sodium
Drug: 3% Menthol
Drug: 0.09% Menthol

First Posted Date: 2014-06-23

Last Posted Date: 2017-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02169154

Locations: 🇺🇸
TKL Research Inc, Paramus, New Jersey, United States

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

Phase 1

Completed

Conditions: Infections, Respiratory Tract

Interventions: Drug: GSK1325756 Solution
Drug: GSK1325756 Solution Matching Placebo
Drug: GSK1325756 Tablet
Drug: GSK1325756 Tablet Matching Placebo